Kintor Pharmaceutical Ltd (hkse:09939) Share Price

Company Profile

Business description
Kintor Pharmaceutical Ltd is a clinical-stage novel drug developer in China focused on the proprietary R&D of drugs for cancers and other AR-related diseases. The company's drug candidate, Pruxelutamide, is a drug undergoing phase III clinical trials in China and phase III clinical trials in the United States for mCRPC as well as clinical trials for breast cancer. Its pipeline of seven drug candidates includes Pruxelutamide (GT0918), Pyrilutamide (KX-826), ALK-1 (GT90001), Detorsertib (GT0486), Hedgehog/SMO Inhibitor (GT1708F), PD-L1/TGF-B (GT90008), and AR-PROTAC Compound (GT20029). The company operates in a single segment focusing on the research and development of medical products.
Contact
No. 20 Songbei Road
Suzhou Industrial Park
Jiangsu
Suzhou215123
CHN
T: +86 51262639909
https://www.kintor.com.cn
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
136

Recommended

We think Microsoft stock is moderately undervalued.

Dan Romanoff, CPA | 30 October 2025

Q3 earnings reflected sequential improvement driven by record auto deliveries and energy storage deployments.

Seth Goldstein, CFA | 30 October 2025

Well priced Aussie shares that offer a tax rebate.

Shani Jayamanne | 29 October 2025

Index	Last price	Change	% Change
All Ordinaries	9,178.00	28.70	-0.31%
CAC 40	8,157.29	43.59	-0.53%
DAX 40	24,118.89	5.32	-0.02%
Dow JONES (US)	47,522.12	109.88	-0.23%
FTSE 100	9,760.06	3.92	0.04%
HKSE	25,999.70	282.99	-1.08%
NASDAQ	23,581.14	377.33	-1.57%
Nikkei 225	52,244.44	918.83	1.79%
NZX 50 Index	13,548.32	89.03	0.66%
S&P 500	6,822.34	68.25	-0.99%
S&P/ASX 200	8,881.90	31.30	-0.35%
SSE Composite Index	3,955.92	30.98	-0.78%